

# NATIONAL QUALITY FORUM

## Measure Submission and Evaluation Worksheet 5.0

This form contains the information submitted by measure developers/stewards, organized according to NQF's measure evaluation criteria and process. The evaluation criteria, evaluation guidance documents, and a blank online submission form are available on the [submitting standards web page](#).

NQF #: 0210	NQF Project: Palliative Care and End-of-Life Care
(for Endorsement Maintenance Review)	
Original Endorsement Date:	Most Recent Endorsement Date:
<b>BRIEF MEASURE INFORMATION</b>	
De.1 Measure Title: <a href="#">Proportion receiving chemotherapy in the last 14 days of life</a>	
Co.1 Measure Steward: <a href="#">American Society of Clinical Oncology   2318 Mill Road, Suite 800   Alexandria   Virginia   22314</a>	
De.2 Brief Description of Measure: <a href="#">Percentage of patients who died from cancer receiving chemotherapy in the last 14 days of life</a>	
2a1.1 Numerator Statement: <a href="#">Patients who died from cancer and received chemotherapy in the last 14 days of life</a>	
2a1.4 Denominator Statement: <a href="#">Patients who died from cancer.</a>	
2a1.8 Denominator Exclusions: <a href="#">None</a>	
1.1 Measure Type: <a href="#">Process</a>	
2a1. 25-26 Data Source: <a href="#">Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Pharmacy, Electronic Clinical Data : Registry, Management Data, Paper Records</a>	
2a1.33 Level of Analysis: <a href="#">Clinician : Group/Practice, Facility, Health Plan, Integrated Delivery System, Population : County or City, Population : National, Population : Regional, Population : State</a>	
1.2-1.4 Is this measure paired with another measure? <a href="#">No</a>	
De.3 If included in a composite, please identify the composite measure ( <i>title and NQF number if endorsed</i> ):	

<b>STAFF NOTES</b> ( <i>issues or questions regarding any criteria</i> )
Comments on Conditions for Consideration:
Is the measure untested? Yes <input type="checkbox"/> No <input type="checkbox"/> If untested, explain how it meets criteria for consideration for time-limited endorsement:
1a. Specific national health goal/priority identified by DHHS or NPP addressed by the measure ( <i>check De.5</i> ):
5. Similar/related <a href="#">endorsed</a> or submitted measures ( <i>check 5.1</i> ):
Other Criteria:
Staff Reviewer Name(s):

<b>1. IMPACT, OPPORTUNITY, EVIDENCE - IMPORTANCE TO MEASURE AND REPORT</b>
Importance to Measure and Report is a threshold criterion that must be met in order to recommend a measure for endorsement. All three subcriteria must be met to pass this criterion. See <a href="#">guidance on evidence</a> . <b><i>Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria. (evaluation criteria)</i></b>
1a. High Impact: H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/> ( <i>The measure directly addresses a specific national health goal/priority identified by DHHS or NPP, or some other high impact</i> )

aspect of healthcare.)			
De.4 Subject/Topic Areas (Check all the areas that apply): Cancer			
De.5 Cross Cutting Areas (Check all the areas that apply): Palliative Care and End of Life Care			
1a.1 Demonstrated High Impact Aspect of Healthcare: Affects large numbers; Patient/societal consequences of poor quality			
1a.2 If "Other," please describe:			
1a.3 Summary of Evidence of High Impact (Provide epidemiologic or resource use data): Chemotherapy use very near death may indicate a lack of honest discussion about disease status and prognosis, poor prognostic ability, and/or toxic death from injudicious use of chemotherapy.			
1a.4 Citations for Evidence of High Impact cited in 1a.3: Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S. Identifying potential indicators of the quality of end of life cancer care from administrative data. J Clin Oncol. 2003;21(6):1133-8.			
1b. Opportunity for Improvement: H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/> (There is a demonstrated performance gap - variability or overall less than optimal performance)			
1b.1 Briefly explain the benefits (improvements in quality) envisioned by use of this measure: Shifting from anti-cancer treatment to supportive treatment earlier would help patients come to terms with their disease, and focus on improving symptoms.			
1b.2 Summary of Data Demonstrating Performance Gap (Variation or overall less than optimal performance across providers): [For Maintenance – Descriptive statistics for performance results for this measure - distribution of scores for measured entities by quartile/decile, mean, median, SD, min, max, etc.] There is regional variation in the use of chemotherapy near death, and its use has been increasing over time.			
1b.3 Citations for Data on Performance Gap: [For Maintenance – Description of the data or sample for measure results reported in 1b.2 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included] Earle CC, Neville BA, Landrum ME, Souza JE, Weeks JC, Block SD, Grunfeld E, Ayanian JZ. Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care. 2005;17(6):505-9. Earle CC, Neville BA, Landrum ME, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22(2):315-21. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol. 2008 Aug 10;26(23):3860-6.			
1b.4 Summary of Data on Disparities by Population Group: [For Maintenance –Descriptive statistics for performance results for this measure by population group] A composite measure of aggressive care that included this measure showed that African-Americans, particularly those treated in the community setting, are more likely to experience aggressive care.			
1b.5 Citations for Data on Disparities Cited in 1b.4: [For Maintenance – Description of the data or sample for measure results reported in 1b.4 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included] Earle CC, Neville BA, Landrum ME, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22(2):315-21. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol. 2008 Aug 10;26(23):3860-6.			
1c. Evidence (Measure focus is a health outcome OR meets the criteria for quantity, quality, consistency of the body of evidence.) Is the measure focus a health outcome? Yes <input type="checkbox"/> No <input type="checkbox"/> If not a health outcome, rate the body of evidence.			
Quantity: H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/> Quality: H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/> Consistency: H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/>			
Quantity	Quality	Consistency	Does the measure pass subcriterion1c?

NQF #0210 Proportion receiving chemotherapy in the last 14 days of life

M-H	M-H	M-H	Yes <input type="checkbox"/>
L	M-H	M	Yes <input type="checkbox"/> IF additional research unlikely to change conclusion that benefits to patients outweigh harms; otherwise No <input type="checkbox"/>
M-H	L	M-H	Yes <input type="checkbox"/> IF potential benefits to patients clearly outweigh potential harms; otherwise No <input type="checkbox"/>
L-M-H	L-M-H	L	No <input type="checkbox"/>
Health outcome – rationale supports relationship to at least one healthcare structure, process, intervention, or service		Does the measure pass subcriterion 1c? Yes <input type="checkbox"/> IF rationale supports relationship	
<p>1c.1 <b>Structure-Process-Outcome Relationship</b> (<i>Briefly state the measure focus, e.g., health outcome, intermediate clinical outcome, process, structure; then identify the appropriate links, e.g., structure-process-health outcome; process- health outcome; intermediate clinical outcome-health outcome</i>):  A structural feature: regional availability of hospice, has been shown to correlate with a composite measure of the aggressiveness of cancer care near the end of life that contains this measure. Mostly it is a process measure indicating a possible inadequate focus on palliation and supportive care, that can affect quality of life.</p> <p>1c.2-3 <b>Type of Evidence</b> (<i>Check all that apply</i>): Selected individual studies (rather than entire body of evidence)</p> <p>1c.4 <b>Directness of Evidence to the Specified Measure</b> (<i>State the central topic, population, and outcomes addressed in the body of evidence and identify any differences from the measure focus and measure target population</i>):  The cited evidence specifically investigates this measure.</p> <p>1c.5 <b>Quantity of Studies in the Body of Evidence</b> (<i>Total number of studies, not articles</i>): 4</p> <p>1c.6 <b>Quality of Body of Evidence</b> (<i>Summarize the certainty or confidence in the estimates of benefits and harms to patients across studies in the body of evidence resulting from study factors. Please address: a) study design/flaws; b) directness/indirectness of the evidence to this measure (e.g., interventions, comparisons, outcomes assessed, population included in the evidence); and c) imprecision/wide confidence intervals due to few patients or events</i>):  The studies are qualitative and observational using administrative data, consequently there are limitations to the quality of the data.</p> <p>1c.7 <b>Consistency of Results across Studies</b> (<i>Summarize the consistency of the magnitude and direction of the effect</i>): All studies have shown similar results.</p> <p>1c.8 <b>Net Benefit</b> (<i>Provide estimates of effect for benefit/outcome; identify harms addressed and estimates of effect; and net benefit - benefit over harms</i>):  A shift from aggressive anti-cancer treatment to supportive care can improve the quality of death. There are no known harms to not giving chemotherapy near death.</p> <p>1c.9 <b>Grading of Strength/Quality of the Body of Evidence</b>. Has the body of evidence been graded? No</p> <p>1c.10 If body of evidence graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias:</p> <p>1c.11 <b>System Used for Grading the Body of Evidence</b>: Other</p> <p>1c.12 If other, identify and describe the grading scale with definitions: N/A</p> <p>1c.13 <b>Grade Assigned to the Body of Evidence</b>:</p> <p>1c.14 <b>Summary of Controversy/Contradictory Evidence</b>:</p> <p>1c.15 <b>Citations for Evidence other than Guidelines</b>(<i>Guidelines addressed below</i>):</p> <p>1c.16 <b>Quote verbatim, the specific guideline recommendation</b> (<i>Including guideline # and/or page #</i>):</p>			

1c.17 Clinical Practice Guideline Citation:

1c.18 National Guideline Clearinghouse or other URL:

1c.19 Grading of Strength of Guideline Recommendation. Has the recommendation been graded? **No**

1c.20 If guideline recommendation graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias:

1c.21 System Used for Grading the Strength of Guideline Recommendation: **Other**

1c.22 If other, identify and describe the grading scale with definitions: **N/A**

1c.23 Grade Assigned to the Recommendation:

1c.24 Rationale for Using this Guideline Over Others:

Based on the NQF descriptions for rating the evidence, what was the developer's assessment of the quantity, quality, and consistency of the body of evidence?

1c.25 Quantity: **High** 1c.26 Quality: **Moderate** 1c.27 Consistency: **High**

Was the threshold criterion, *Importance to Measure and Report*, met?

(1a & 1b must be rated moderate or high and 1c yes) Yes  No

Provide rationale based on specific subcriteria:

**For a new measure if the Committee votes NO, then STOP.**

**For a measure undergoing endorsement maintenance, if the Committee votes NO because of 1b. (no opportunity for improvement), it may be considered for continued endorsement and all criteria need to be evaluated.**

## 2. RELIABILITY & VALIDITY - SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (evaluation criteria)

Measure testing must demonstrate adequate reliability and validity in order to be recommended for endorsement. Testing may be conducted for data elements and/or the computed measure score. Testing information and results should be entered in the appropriate field. Supplemental materials may be referenced or attached in item 2.1. See [guidance on measure testing](#).

S.1 Measure Web Page (In the future, NQF will require measure stewards to provide a URL link to a web page where current detailed specifications can be obtained). Do you have a web page where current detailed specifications for this measure can be obtained? **No**

S.2 If yes, provide web page URL:

2a. RELIABILITY. Precise Specifications and Reliability Testing: H  M  L  I

2a1. Precise Measure Specifications. (The measure specifications precise and unambiguous.)

2a1.1 Numerator Statement (Brief, narrative description of the measure focus or what is being measured about the target population, e.g., cases from the target population with the target process, condition, event, or outcome):

**Patients who died from cancer and received chemotherapy in the last 14 days of life**

2a1.2 Numerator Time Window (The time period in which the target process, condition, event, or outcome is eligible for inclusion):

**14 days prior to death**

2a1.3 Numerator Details (All information required to identify and calculate the cases from the target population with the target process, condition, event, or outcome such as definitions, codes with descriptors, and/or specific data collection items/responses):

NQF #0210 Proportion receiving chemotherapy in the last 14 days of life

ICD-9: 140 – 239  
Chemotherapy administration codes:  
ICD-9 diagnosis codes: V58.1  
OR  
ICD-9 procedure codes: 99.25  
OR  
CPT codes: 964xx, 965xx  
OR  
HCPCS codes: J7150, J85xx, J86xx, J87xx, J8999, J9xxx, Q0083, Q0084, Q0085  
OR  
DRG codes: 410  
OR  
Revenue center codes: 0331, 0332, 0335  
OR  
BETOS codes: O1D  
OR  
NDC Brand descriptions: Alkeran, Cytoxan, Methotrexate Sodium, Temodar, VePesid, Xeloda

**2a1.4 Denominator Statement** (Brief, narrative description of the target population being measured):  
Patients who died from cancer.

**2a1.5 Target Population Category** (Check all the populations for which the measure is specified and tested if any): [Adult/Elderly Care](#)

**2a1.6 Denominator Time Window** (The time period in which cases are eligible for inclusion):  
[None](#)

**2a1.7 Denominator Details** (All information required to identify and calculate the target population/denominator such as definitions, codes with descriptors, and/or specific data collection items/responses):  
[Medicare patients in the death registry with cancer as their cause of death](#)

**2a1.8 Denominator Exclusions** (Brief narrative description of exclusions from the target population):  
[None](#)

**2a1.9 Denominator Exclusion Details** (All information required to identify and calculate exclusions from the denominator such as definitions, codes with descriptors, and/or specific data collection items/responses):  
[N/A](#)

**2a1.10 Stratification Details/Variables** (All information required to stratify the measure results including the stratification variables, codes with descriptors, definitions, and/or specific data collection items/responses):  
[None](#)

**2a1.11 Risk Adjustment Type** (Select type. Provide specifications for risk stratification in 2a1.10 and for statistical model in 2a1.13): [No risk adjustment or risk stratification](#) 2a1.12 If "Other," please describe:

**2a1.13 Statistical Risk Model and Variables** (Name the statistical method - e.g., logistic regression and list all the risk factor variables. Note - risk model development should be addressed in 2b4.):  
[N/A](#)

**2a1.14-16 Detailed Risk Model Available at Web page URL** (or attachment). Include coefficients, equations, codes with descriptors, definitions, and/or specific data collection items/responses. Attach documents only if they are not available on a webpage and keep attached file to 5 MB or less. NQF strongly prefers you make documents available at a Web page URL. Please supply login/password if needed:

**2a1.17-18. Type of Score:** [Rate/proportion](#)

2a1.19 **Interpretation of Score** (Classifies interpretation of score according to whether better quality is associated with a higher score, a lower score, a score falling within a defined interval, or a passing score): [better quality = lower score](#)

2a1.20 **Calculation Algorithm/Measure Logic**(Describe the calculation of the measure score as an ordered sequence of steps including identifying the target population; exclusions; cases meeting the target process, condition, event, or outcome; aggregating data; risk adjustment; etc.):

2a1.21 – 23 **Calculation Algorithm/Measure Logic Diagram URL or attachment:**

2a1.24 **Sampling (Survey) Methodology.** If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate):

2a1.25 **Data Source** (Check all the sources for which the measure is specified and tested). If other, please describe: [Administrative claims](#), [Electronic Clinical Data](#), [Electronic Clinical Data : Electronic Health Record](#), [Electronic Clinical Data : Pharmacy](#), [Electronic Clinical Data : Registry](#), [Management Data](#), [Paper Records](#)

2a1.26 **Data Source/Data Collection Instrument** (Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.): [Medicare claims and denominator file](#)

2a1.27-29 **Data Source/data Collection Instrument Reference Web Page URL or Attachment:**

2a1.30-32 **Data Dictionary/Code Table Web Page URL or Attachment:**

2a1.33 **Level of Analysis** (Check the levels of analysis for which the measure is specified and tested): [Clinician : Group/Practice](#), [Facility](#), [Health Plan](#), [Integrated Delivery System](#), [Population : County or City](#), [Population : National](#), [Population : Regional](#), [Population : State](#)

2a1.34-35 **Care Setting** (Check all the settings for which the measure is specified and tested): [Ambulatory Care : Clinician Office](#), [Hospital/Acute Care Facility 111253](#)

2a2. **Reliability Testing.** (Reliability testing was conducted with appropriate method, scope, and adequate demonstration of reliability.)

2a2.1 **Data/Sample** (Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

[The measure was developed using the Medicare claims of all continuously-enrolled patients who died of cancer after having been diagnosed in a SEER region between 1991 and 1996.](#)

2a2.2 **Analytic Method** (Describe method of reliability testing & rationale):

[Evaluation was carried out on 150 consecutive patients treated for advanced cancer at Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston. Claims were obtained and analyzed and the accuracy was compared to detailed medical record review.](#)

2a2.3 **Testing Results** (Reliability statistics, assessment of adequacy in the context of norms for the test conducted):

[Sensitivity 0.92, Specificity 0.94](#)

2b. **VALIDITY. Validity, Testing, including all Threats to Validity:** H  M  L  I

2b1.1 **Describe how the measure specifications** (measure focus, target population, and exclusions) **are consistent with the evidence cited in support of the measure focus** (criterion 1c) **and identify any differences from the evidence:**

[They are identical](#)

2b2. **Validity Testing.** (Validity testing was conducted with appropriate method, scope, and adequate demonstration of validity.)

2b2.1 **Data/Sample** (Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

[Evaluation was carried out on 150 consecutive patients treated for advanced cancer at Dana-Farber Cancer Institute and Brigham](#)

and Women’s Hospital in Boston. Claims were obtained and analyzed and the accuracy was compared to detailed medical record review.

**2b2.2 Analytic Method** (Describe method of validity testing and rationale; if face validity, describe systematic assessment):  
The percent agreement between claims and medical record review was calculated.

**2b2.3 Testing Results** (Statistical results, assessment of adequacy in the context of norms for the test conducted; if face validity, describe results of systematic assessment):  
The measure was 92% accurate.

**POTENTIAL THREATS TO VALIDITY.** (All potential threats to validity were appropriately tested with adequate results.)

**2b3. Measure Exclusions.** (Exclusions were supported by the clinical evidence in 1c or appropriately tested with results demonstrating the need to specify them.)

**2b3.1 Data/Sample for analysis of exclusions** (Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):  
None

**2b3.2 Analytic Method** (Describe type of analysis and rationale for examining exclusions, including exclusion related to patient preference):  
N/A

**2b3.3 Results** (Provide statistical results for analysis of exclusions, e.g., frequency, variability, sensitivity analyses):  
N/A

**2b4. Risk Adjustment Strategy.** (For outcome measures, adjustment for differences in case mix (severity) across measured entities was appropriately tested with adequate results.)

**2b4.1 Data/Sample** (Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):  
N/A

**2b4.2 Analytic Method** (Describe methods and rationale for development and testing of risk model or risk stratification including selection of factors/variables):  
N/A

**2b4.3 Testing Results** (Statistical risk model: Provide quantitative assessment of relative contribution of model risk factors; risk model performance metrics including cross-validation discrimination and calibration statistics, calibration curve and risk decile plot, and assessment of adequacy in the context of norms for risk models. Risk stratification: Provide quantitative assessment of relationship of risk factors to the outcome and differences in outcomes among the strata):  
N/A

**2b4.4 If outcome or resource use measure is not risk adjusted, provide rationale and analyses to justify lack of adjustment:**

**2b5. Identification of Meaningful Differences in Performance.** (The performance measure scores were appropriately analyzed and discriminated meaningful differences in quality.)

**2b5.1 Data/Sample** (Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):  
We used the Medicare claims of all 28,777 continuously-enrolled patients who died of cancer after having been diagnosed in a SEER region between 1991 and 1996.

**2b5.2 Analytic Method** (Describe methods and rationale to identify statistically significant and practically/meaningfully differences in performance):  
Benchmarks were established to identify the outlying 10th decile of practice

**2b5.3 Results** (Provide measure performance results/scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningful differences in performance):

A benchmark target of < 10% of patients receiving chemotherapy in the last 14 days of life.

**2b6. Comparability of Multiple Data Sources/Methods.** (If specified for more than one data source, the various approaches result in comparable scores.)

**2b6.1 Data/Sample** (Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

Administrative claims and chart review, as described above.

**2b6.2 Analytic Method** (Describe methods and rationale for testing comparability of scores produced by the different data sources specified in the measure):

% agreement was calculated

**2b6.3 Testing Results** (Provide statistical results, e.g., correlation statistics, comparison of rankings; assessment of adequacy in the context of norms for the test conducted):

92% accuracy

**2c. Disparities in Care:** H  M  L  I  NA  (If applicable, the measure specifications allow identification of disparities.)

**2c.1** If measure is stratified for disparities, provide stratified results (Scores by stratified categories/cohorts): N/A

**2c.2** If disparities have been reported/identified (e.g., in 1b), but measure is not specified to detect disparities, please explain:

N/A

**2.1-2.3 Supplemental Testing Methodology Information:**

**Steering Committee:** Overall, was the criterion, *Scientific Acceptability of Measure Properties*, met?

(Reliability and Validity must be rated moderate or high) Yes  No

Provide rationale based on specific subcriteria:

**If the Committee votes No, STOP**

### 3. USABILITY

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (**evaluation criteria**)

**C.1 Intended Purpose/ Use** (Check all the purposes and/or uses for which the measure is intended): Public Reporting, Quality Improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

**3.1 Current Use** (Check all that apply; for any that are checked, provide the specific program information in the following questions): Public Reporting; Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

**3a. Usefulness for Public Reporting:** H  M  L  I

(The measure is meaningful, understandable and useful for public reporting.)

**3a.1. Use in Public Reporting - disclosure of performance results to the public at large** (If used in a public reporting program, provide name of program(s), locations, Web page URL(s)). If not publicly reported in a national or community program, state the reason AND plans to achieve public reporting, potential reporting programs or commitments, and timeline, e.g., within 3 years of endorsement: [For **Maintenance** – If not publicly reported, describe progress made toward achieving disclosure of performance results to the public at large and expected date for public reporting; provide rationale why continued endorsement should be considered.]

This has been reported as part of Cancer Care Ontario's Cancer System Quality Index ([www.csqi.cancercare.on.ca](http://www.csqi.cancercare.on.ca)) and ASCO's



QOPI program ([www.qopi.asco.org](http://www.qopi.asco.org))

3a.2. Provide a rationale for why the measure performance results are meaningful, understandable, and useful for public reporting. If usefulness was demonstrated (e.g., focus group, cognitive testing), describe the data, method, and results: [This measure was established based on focus groups and interviews with patients, followed by a modified Delphi process with an expert panel.](#)

3.2 Use for other Accountability Functions (payment, certification, accreditation). If used in a public accountability program, provide name of program(s), locations, Web page URL(s):

3b. Usefulness for Quality Improvement: H  M  L  I   
 (The measure is meaningful, understandable and useful for quality improvement.)

3b.1. Use in QI. If used in quality improvement program, provide name of program(s), locations, Web page URL(s):  
 [For **Maintenance** – If not used for QI, indicate the reasons and describe progress toward using performance results for improvement].

[The measure indicates whether honest discussions about prognosis and likelihood of benefit from treatment have taken place.](#)

3b.2. Provide rationale for why the measure performance results are meaningful, understandable, and useful for quality improvement. If usefulness was demonstrated (e.g., QI initiative), describe the data, method and results:  
[The measure has face validity and is largely under the control of the treating physician.](#)

Overall, to what extent was the criterion, *Usability*, met? H  M  L  I   
 Provide rationale based on specific subcriteria:

#### 4. FEASIBILITY

Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)

4a. Data Generated as a Byproduct of Care Processes: H  M  L  I

4a.1-2 How are the data elements needed to compute measure scores generated? (Check all that apply).

Data used in the measure are: [Coded by someone other than person obtaining original information \(e.g., DRG, ICD-9 codes on claims\)](#)

4b. Electronic Sources: H  M  L  I

4b.1 Are the data elements needed for the measure as specified available electronically (Elements that are needed to compute measure scores are in defined, computer-readable fields): [ALL data elements in electronic claims](#)

4b.2 If ALL data elements are not from electronic sources, specify a credible, near-term path to electronic capture, OR provide a rationale for using other than electronic sources:

4c. Susceptibility to Inaccuracies, Errors, or Unintended Consequences: H  M  L  I

4c.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measurement identified during testing and/or operational use and strategies to prevent, minimize, or detect. If audited, provide results:  
[92% accuracy](#)

4d. Data Collection Strategy/Implementation: H  M  L  I

A.2 Please check if either of the following apply (regarding proprietary measures):

4d.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, other feasibility/implementation issues (e.g., fees for use of proprietary measures):  
[None](#)

Overall, to what extent was the criterion, *Feasibility*, met? H  M  L  I   
 Provide rationale based on specific subcriteria:

### OVERALL SUITABILITY FOR ENDORSEMENT

Does the measure meet all the NQF criteria for endorsement? Yes  No

Rationale:

**If the Committee votes No, STOP.**

**If the Committee votes Yes, the final recommendation is contingent on comparison to related and competing measures.**

### 5. COMPARISON TO RELATED AND COMPETING MEASURES

If a measure meets the above criteria and there are endorsed or new related measures (either the same measure focus or the same target population) or competing measures (both the same measure focus and the same target population), the measures are compared to address harmonization and/or selection of the best measure before a final recommendation is made.

5.1 If there are related measures (*either same measure focus or target population*) or competing measures (*both the same measure focus and same target population*), list the NQF # and title of all related and/or competing measures:

0211 : Proportion with more than one emergency room visit in the last days of life

0212 : Proportion with more than one hospitalization in the last 30 days of life

0213 : Proportion admitted to the ICU in the last 30 days of life

0214 : Proportion dying from Cancer in an acute care setting

0215 : Proportion not admitted to hospice

0216 : Proportion admitted to hospice for less than 3 days

#### 5a. Harmonization

5a.1 If this measure has EITHER the same measure focus OR the same target population as [NQF-endorsed measure\(s\)](#): Are the measure specifications completely harmonized?

5a.2 If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden:

#### 5b. Competing Measure(s)

5b.1 If this measure has both the same measure focus and the same target population as NQF-endorsed measure(s): Describe why this measure is superior to competing measures (*e.g., a more valid or efficient way to measure quality*); OR provide a rationale for the additive value of endorsing an additional measure. (*Provide analyses when possible*):

### CONTACT INFORMATION

Co.1 Measure Steward (Intellectual Property Owner): [American Society of Clinical Oncology | 2318 Mill Road, Suite 800 | Alexandria | Virginia | 22314](#)

Co.2 Point of Contact: [Craig | Earle, MD | craig.earle@ices.on.ca | 416-480-6047-](#)

Co.3 Measure Developer if different from Measure Steward: [Institute for Clinical Evaluative Sciences | 2075 Bayview Ave, G-wing, room 106 | Toronto | Ontario, M4N 3M5](#)

Co.4 Point of Contact: [Craig | Earle, MD | craig.earle@ices.on.ca | 416-480-6047-](#)

Co. 5 Submitter: [Craig | Earle, MD | craig.earle@ices.on.ca | 416-480-6047- | Institute for Clinical Evaluative Sciences](#)

Co.6 Additional organizations that sponsored/participated in measure development:

Co.7 Public Contact: [Craig | Earle, MD | craig.earle@ices.on.ca | 416-480-6047- | Institute for Clinical Evaluative Sciences](#)

**ADDITIONAL INFORMATION**

Workgroup/Expert Panel involved in measure development

Ad.1 Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development.

Co-investigators on grant: [Jane Weeks](#), [John Ayanian](#), [Mary Beth Landrum](#), [Susan Block](#), [Joe Newhouse](#)

Ad.2 If adapted, provide title of original measure, NQF # if endorsed, and measure steward. Briefly describe the reasons for adapting the original measure and any work with the original measure steward:

Measure Developer/Steward Updates and Ongoing Maintenance

Ad.3 Year the measure was first released: [2005](#)

Ad.4 Month and Year of most recent revision: [06/2011](#)

Ad.5 What is your frequency for review/update of this measure? [q3years](#)

Ad.6 When is the next scheduled review/update for this measure? [12/2013](#)

Ad.7 Copyright statement/disclaimers:

Ad.8 Additional Information/Comments:

Date of Submission (MM/DD/YY): [Aug 10, 2009](#)